Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 2/20 | 0.59 |
| ▸ | DRD2 | P14416 | 2/20 | 0.59 |
| ▸ | ABCB1 | P08183 | 6/20 | 0.56 |
| ▸ | PTGER1 | P34995 | 4/20 | 0.56 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.56 |
| ▸ | PTGER3 | P43115 | 4/20 | 0.56 |
| ▸ | PTGER2 | P43116 | 4/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | BRD4 | O60885 | 1/20 | 0.51 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.49 |
| ▸ | MGLL | Q99685 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7990040 | 0.92 | PTGER1 (0.60) | HTR1ADRD2ABCB1PTGER1PTGER4 | |
| SCHEMBL19161215 | 0.86 | ABCB1 (0.57) | HTR1ADRD2ABCB1 | |
| SCHEMBL9122305 | 0.86 | ABCB1 (0.50) | HTR1ADRD2ABCB1PTGER1PTGER4 | |
| SCHEMBL31757763 | 0.85 | L3MBTL1 (0.56) | HTR1ADRD2ABCB1PTGER1PTGER4 | |
| SCHEMBL28140607 | 0.85 | HTR1A (0.63) | HTR1ADRD2ABCB1PTGER1PTGER4 | |
| SCHEMBL2988197 | 0.85 | L3MBTL1 (0.56) | HTR1ADRD2ABCB1PTGER1PTGER4 | |
| SCHEMBL2985026 | 0.85 | LMNA (0.51) | HTR1ADRD2ABCB1PTGER1PTGER4 | |
| SCHEMBL2038509 | 0.84 | PTGER1 (0.67) | HTR1ADRD2ABCB1PTGER1PTGER4 | |
| SCHEMBL8493897 | 0.84 | HTR1A (0.58) | HTR1ADRD2ABCB1PTGER1PTGER4 | |
| SCHEMBL16293563 | 0.84 | CCR5 (0.57) | PTGER1PTGER4PTGER3PTGER2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044063-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Astra Zeneca AB (SE) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008001070-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | disclosed |
| US-20080004302-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | US | disclosed |
| CN-1075808-C | Aniline derivatives having nitric oxide synthase inhibitory activity | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2001-12-05 | — | — | CN | disclosed |
| US-6207686-B1 | FOR THERAPY OF HYPERTENSION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-03-27 | — | — | US | disclosed |
| EP-0733033-B1 | PHARMACEUTICALLY ACTIVE SUBSTITUTED AROMATIC COMPOUNDS | ZENECA LTD (GB) | 1999-12-22 | — | — | EP | disclosed |
| US-5811459-A | PAIN RELIEVERS | ZENECA LIMITED (GB) | 1998-09-22 | — | — | US | disclosed |
| EP-0792265-A1 | ENDOTHELIN ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-09-03 | — | — | EP | disclosed |
| EP-0733033-A1 | PHARMACEUTICALLY ACTIVE SUBSTITUTED AROMATIC COMPOUNDS | ZENECA LIMITED (GB) | 1996-09-25 | — | — | EP | disclosed |
| WO-1996015109-A1 | ENDOTHELIN ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-05-23 | — | — | WO | disclosed |
| WO-1996011902-A1 | PHARMACEUTICALLY ACTIVE SUBSTITUTED AROMATIC COMPOUNDS | ZENECA LIMITED (GB) | 1996-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004302-A1 | Novel Compounds | CYP11B2, CYP11B1, CYP46A1 | HTR1A 1963/4885DRD2 4059/4885ABCB1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.